GeoVax Labs, Inc. (GOVX)
| Market Cap | 3.18M |
| Revenue (ttm) | 2.49M |
| Net Income (ttm) | -21.46M |
| Shares Out | 2.89M |
| EPS (ttm) | -22.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 92,584 |
| Open | 1.120 |
| Previous Close | 1.110 |
| Day's Range | 1.100 - 1.140 |
| 52-Week Range | 1.090 - 34.750 |
| Beta | 3.80 |
| Analysts | Hold |
| Price Target | 1.00 (-9.09%) |
| Earnings Date | Apr 15, 2026 |
About GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vacc... [Read more]
Financial Performance
In 2025, GeoVax Labs's revenue was $2.49 million, a decrease of -37.06% compared to the previous year's $3.95 million. Losses were -$21.46 million, -14.11% less than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for GOVX stock is "Hold" and the 12-month stock price target is $1.0.
News
GeoVax Labs Transcript: Biotech Showcase 2026
Multiple clinical-stage programs are advancing, with GEO-MVA set for a phase III trial and aiming to address global vaccine shortages. Manufacturing innovations and strategic partnerships are expected to accelerate commercialization, while financial strategy focuses on non-dilutive funding and expedited regulatory pathways.
GeoVax Labs Earnings Call Transcript: Q3 2025
GEO-MVA received expedited EMA guidance, enabling a direct phase III trial and accelerating market entry. Revenue declined due to BARDA contract termination, while R&D expenses fell and cash reserves remain tight. Strategic partnerships and manufacturing scale-up are key priorities.
GeoVax Labs Transcript: Emerging Growth Conference 2025
GEO-CM04S1 vaccine trials show superior immune response in immunocompromised patients, with ongoing studies expected to complete by year-end. The company is raising additional capital and advancing other vaccine and therapy programs, while maintaining strong investor engagement.
GeoVax Labs Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The presentation highlighted innovative vaccine and immunotherapy programs targeting infectious diseases and cancer, with expedited regulatory pathways and large market opportunities. Key products are advancing through clinical trials, with strong differentiation and global commercialization plans.
GeoVax Labs Transcript: Emerging Growth Conference 85
Focused on vaccines for infectious diseases and cancer, the company advances three priority programs targeting large, underserved markets. Strategic alignment with U.S. government priorities, robust capital-raising, and plans to break a major vaccine monopoly position it for revenue generation within three years.
GeoVax Labs Earnings Call Transcript: Q2 2025
GEO-MVA received expedited EMA guidance to proceed directly to a phase III trial, while Gedeptin and GEO-CM04S1 advance in oncology and COVID-19 indications, respectively. Revenue rose sharply year-over-year, but the BARDA contract termination impacts future income. Cash was bolstered by a $6M July offering.
GeoVax Labs Earnings Call Transcript: Q1 2025
Q1 2025 saw increased R&D and administrative expenses, with a net loss of $5.4M and cash rising to $7.4M after financing. Despite the BARDA contract termination, clinical programs for COVID-19, mpox, and oncology vaccines remain on track, with a focus on immunocompromised populations and U.S.-based manufacturing.
GeoVax Labs Earnings Call Transcript: Q4 2024
Secured major BARDA funding for next-gen COVID-19 vaccine, advanced mpox/smallpox and oncology programs, and reported a $25M net loss for 2024. R&D spending rose, cash runway supported by new financing, and global partnerships are a key focus.
GeoVax Labs Transcript: Emerging Growth Conference 79
Three major programs are advancing: a next-gen COVID-19 vaccine, a Mpox vaccine addressing urgent global shortages, and a solid tumor therapy. The Mpox vaccine is nearing clinical evaluation and may generate initial revenue, with expanded manufacturing planned.
GeoVax Labs Transcript: Emerging Growth Conference 78
The company is advancing three main programs: a next-gen COVID-19 vaccine with a $400M BARDA-backed trial, a low-cost mpox/smallpox vaccine targeting urgent global needs, and Gedeptin for solid tumors, with multiple clinical milestones and funding efforts underway. Key catalysts are expected over the next two years.
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vacci...
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chai...
GeoVax Labs Earnings Call Transcript: Q3 2024
Secured a major BARDA award to fund a pivotal COVID-19 vaccine trial, advanced key oncology and infectious disease programs, and improved financial flexibility through recent financings. Revenue growth and R&D investment reflect progress, with major clinical milestones expected in late 2024 and early 2025.
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancer...
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its...
GeoVax Labs Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024
The conference highlighted innovative vaccine and immunotherapy programs targeting unmet needs, including a next-gen COVID-19 vaccine with robust, durable protection, mpox vaccine supply expansion, and a tumor-agnostic therapy advancing to phase II. Significant market opportunities and global collaborations were emphasized.
GeoVax to Participate in Upcoming Investor Conferences in September
ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announc...
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, ...
GeoVax's stock slides 20% after company raises $8.5 million in stock sale
GeoVax Labs Inc.'s stock GOVX, +1.27% tumbled 20% in premarket trade Tuesday, after the clinical-stage biotech said it's entered an agreement with an institutional investor for the purchase and sale o...
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
ATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, ...
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now
MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.
GeoVax's stock soars 54% to lead rally in companies developing mpox treatments
GeoVax Labs Inc.'s stock soared 54% early Monday to lead a fresh rally among companies developing treatments for mpox, after rival Siga Technologies Inc. said a trial of its antiviral failed to meet i...
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
Company to Discuss Recent Mpox Developments as Well as Milestones Related to the BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine
Mpox outbreak: 5 stocks to watch out for as the emergency unfolds
The World Health Organisation on Wednesday declared the upsurge of monkeypox virus or ‘Mpox' in Africa a public health emergency of international concern (PHEIC), stating it had the potential to sprea...